Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inhibrx Biosciences, Inc. (INBX : NSDQ)
 
 • Company Description   
Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

Number of Employees: 161

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.33 Daily Weekly Monthly
20 Day Moving Average: 81,386 shares
Shares Outstanding: 14.48 (millions)
Market Capitalization: $236.39 (millions)
Beta: -0.04
52 Week High: $17.79
52 Week Low: $10.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 26.69% 19.83%
12 Week 44.26% 21.02%
Year To Date 6.04% -0.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11025 N. TORREY PINES ROAD SUITE 140
-
LA JOLLA,CA 92037
USA
ph: 858-795-4220
fax: -
ir@inhibrx.com https://inhibrx.com
 
 • General Corporate Information   
Officers
Mark P. Lappe - Chief Executive Officer and Chairman
Kelly D. Deck - Chief Financial Officer
Jon Faiz Kayyem - Director
Douglas G. Forsyth - Director
Kimberly Manhard - Director

Peer Information
Inhibrx Biosciences, Inc. (CORR.)
Inhibrx Biosciences, Inc. (RSPI)
Inhibrx Biosciences, Inc. (CGXP)
Inhibrx Biosciences, Inc. (BGEN)
Inhibrx Biosciences, Inc. (GTBP)
Inhibrx Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45720N103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 14.48
Most Recent Split Date: (:1)
Beta: -0.04
Market Capitalization: $236.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.94 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-11.67 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 0.14
PEG Ratio: -
Price Ratios
Price/Book: 2.50
Price/Cash Flow: 0.14
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 9.39%
Sales Growth
vs. Year Ago Period: -93.94%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -85.12
12/31/24 - -129.52
ROA
06/30/25 - -
03/31/25 - -58.90
12/31/24 - -97.73
Current Ratio
06/30/25 - -
03/31/25 - 5.12
12/31/24 - 3.94
Quick Ratio
06/30/25 - -
03/31/25 - 5.12
12/31/24 - 3.94
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - 861,486.44
12/31/24 - 843,787.00
Book Value
06/30/25 - -
03/31/25 - 6.52
12/31/24 - 9.23
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.04
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 51.09
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©